Nexara Health — Health Canada Drug Establishment Licence #3-002896

SODIUM ACETATE INJECTION USP 328 MG

Last verified 2026-09-08 · Source: Health Canada Drug Product Database (DPD), DIN 02181746

SODIUM ACETATE INJECTION USP 328 MG

SODIUM ACETATE 328 MG · DIN 02181746 · OMEGA LABORATORIES LIMITED

Health Canada status: MARKETED

SODIUM ACETATE INJECTION USP 328 MG Solution - DIN 02181746
SODIUM ACETATE INJECTION USP — DIN 02181746. Product photograph held by Nexara Health.

What is SODIUM ACETATE INJECTION USP?

SODIUM ACETATE INJECTION USP 328 MG contains SODIUM ACETATE 328 MG. It is listed in the Health Canada Drug Product Database under DIN 02181746, held by OMEGA LABORATORIES LIMITED, supplied as Solution for Intravenous administration. Health Canada currently lists it as marketed, status dated 11-Jan-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is SODIUM ACETATE INJECTION USP used for?

Sodium Acetate Injection USP is indicated as a source of sodium, for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02181746
Brand nameSODIUM ACETATE INJECTION USP
Generic / active ingredientSODIUM ACETATE 328 MG
ManufacturerOMEGA LABORATORIES LIMITED
Strength328 MG
Dosage formSolution
Route of administrationIntravenous
ScheduleETHICAL
ATC codeB05XA08 SODIUM ACETATE
AHFS class40:12.00
BiosimilarNo
Health Canada statusMARKETED
Status date11-Jan-2024
Original market date1999-05-28 00:00:00

How is it administered?

Sodium Acetate Injection USP is administered intravenously only after dilution in a larger volume of intravenous fluids. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of milliequivalents (mEq) of sodium with an equal number of acetate. Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Protect from light. Store between 15 °C and 30 °C. Do not freeze. Discard unused portion.

How is it supplied?

Single use vials of 50 mL in boxes of 10.

Contraindications

Sodium Acetate Injection USP is contraindicated in patients with hypernatremia or fluid retention.

Warnings and precautions

Sodium Acetate Injection USP must be diluted before use. To avoid sodium overload and water retention, infuse sodium-containing solutions slowly. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. The intravenous administration of this solution (after appropriate dilution) can cause fluid and/or solute overloading resulting in dilution of other serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excessive administration of potassium-free solutions may result in significant hypokalemia.

Is SODIUM ACETATE in shortage in Canada?

A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for SODIUM ACETATE INJECTION USP

What can be used instead?

Other Canadian products sharing ATC code B05XA08 SODIUM ACETATE. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
SODIUM ACETATE INJECTION, USP328 MGSOLUTIONFRESENIUS KABI CANADA LTDMARKETEDDIN 02139529
16.4% SODIUM ACETATE INJECTION, USP16.4 %SOLUTIONBAXTER CORPORATIONCANCELLED POST MARKETDIN 02247204
SODIUM ACETATE INJ 328MG/ML USP328 MGLIQUIDSABEX INCCANCELLED POST MARKETDIN 00780642
SODIUM ACETATE INJ 328MG/ML USP328 MGLIQUIDLYPHOMED, DIVISION OF FUJISAWA CANADA INC.CANCELLED POST MARKETDIN 01944843

Who else supplies SODIUM ACETATE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. SODIUM ACETATE appears in 5432 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for SODIUM ACETATE INJECTION USP

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Related pages

Sourcing this product